Bone Fracture - Pipeline Review, H2 2018

Bone Fracture - Pipeline Review, H2 2018


  • Products Id :- GMDHC10794IDB
  • |
  • Pages: 75
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Bone Fracture-Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Bone Fracture-Pipeline Review, H2 2018, provides an overview of the Bone Fracture (Musculoskeletal Disorders) pipeline landscape.

Fractures are simply a break in a bone caused by forces that exceed the strength of the osseous tissue in the bone. Signs and symptoms of a fracture include swelling or bruising over a bone, deformity of an arm or leg, loss of function in the injured area and in compound fractures, bone protruding from the skin.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Bone Fracture-Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Bone Fracture (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Bone Fracture (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Bone Fracture and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 6, 1, 5 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 3 molecules, respectively.

Bone Fracture (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Bone Fracture (Musculoskeletal Disorders).

- The pipeline guide reviews pipeline therapeutics for Bone Fracture (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Bone Fracture (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Bone Fracture (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Bone Fracture (Musculoskeletal Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Bone Fracture (Musculoskeletal Disorders).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Bone Fracture (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Bone Fracture-Overview

Bone Fracture-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Bone Fracture-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Bone Fracture-Companies Involved in Therapeutics Development

Biopharm GmbH

Bone Therapeutics SA

Entera Bio Ltd

ethris GmbH

Hemostemix Inc

Kolon TissueGene Inc

Kuros Biosciences AG

Laboratorios SALVAT SA

Novartis AG

Viking Therapeutics Inc

Bone Fracture-Drug Profiles

ALLOB-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BCP-01-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bimagrumab-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cyndacel-M-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drugs to Modulate PPAR-Delta for Metabolic and Musculoskeletal Disorders-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy for Bone Fracture-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate BMP2 and VEGF for Bone Fracture-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HCSVT-1001-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KUR-111-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KUR-113-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Oligonucleotide to Activate BMP-2 for Bone Fracture-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Peptide to Agonize PTH1R for Bone Fracture-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein for Bone Fracture, Degenerative Disc Disease, Erectile Dysfunction and Parkinson's Disease-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

S-008399-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Metabolic and Musculoskeletal Disorders-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Musculoskeletal and Metabolic Disorders-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptide for Osteoporosis and Bone Fracture-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TG-B-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VK-5211-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Bone Fracture-Dormant Projects

Bone Fracture-Discontinued Products

Bone Fracture-Product Development Milestones

Featured News & Press Releases

Jul 17, 2018: Viking Therapeutics Announces VK5211 Phase 2 Study Results Selected for Plenary Oral Presentation at ASBMR 2018 Annual Meeting

Feb 19, 2018: Bone Therapeutics completes patient recruitment for Phase IIA Spinal Fusion study with ALLOB

Nov 28, 2017: Viking Therapeutics Announces Positive Top-Line Results from Phase 2 Study of VK5211 in Patients Recovering from Hip Fracture

Sep 25, 2017: Viking Therapeutics to Host Key Opinion Leader Event to Discuss Musculoskeletal Therapeutics in Hip Fracture and Other Settings

Sep 20, 2017: Bone Therapeutics: announces all patients meet primary endpoint in ALLOB Phase I/IIA delayed-union study interim analysis

Sep 14, 2017: Bone Therapeutics: Reports strong interim results from ALLOB Phase IIA spinal fusion study

Jul 12, 2017: Viking Therapeutics Completes Enrollment in Phase 2 Study of VK5211 in Patients Recovering from Hip Fracture

Mar 09, 2017: Bone Therapeutics Completes Recruitment of 16 Patients in ALLOB PHASE I/IIA Delayed-Union Study

Oct 05, 2016: Bone Therapeutics reports positive efficacy data for the ALLOB Phase IIA spinal fusion trial

Sep 01, 2016: Viking Therapeutics Presents Phase 1 Data and Highlights Ongoing Phase 2 Study of VK5211 at 5th Fragility Fracture Network Global Congress 2016

May 03, 2016: Bone Therapeutics completes recruitment of its ALLOB Phase IIA spinal fusion study

Feb 24, 2016: Bone Therapeutics Presents ALLOB Pre-Clinical and Early Clinical Efficacy Data in Spinal Fusion at the 'Clinical Applications of Stem Cells' Conference

Feb 17, 2016: Bone Therapeutics treats 12 patients without safety concerns in ALLOB Phase IIA spinal fusion trial

Nov 03, 2015: Viking Therapeutics Initiates Phase 2 Trial of VK5211 in Patients Recovering From Hip Fracture

Oct 20, 2015: Viking Therapeutics Completes Safety, Tolerability and Pharmacokinetic Study of VK5211, a Selective Androgen Receptor Modulator, in Healthy Elderly Subjects

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Figures

Number of Products under Development for Bone Fracture, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Number of Products by Targets, H2 2018

Number of Products by Stage and Targets, H2 2018

Number of Products by Mechanism of Actions, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018

List of Tables

Number of Products under Development for Bone Fracture, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Bone Fracture-Pipeline by Biopharm GmbH, H2 2018

Bone Fracture-Pipeline by Bone Therapeutics SA, H2 2018

Bone Fracture-Pipeline by Entera Bio Ltd, H2 2018

Bone Fracture-Pipeline by ethris GmbH, H2 2018

Bone Fracture-Pipeline by Hemostemix Inc, H2 2018

Bone Fracture-Pipeline by Kolon TissueGene Inc, H2 2018

Bone Fracture-Pipeline by Kuros Biosciences AG, H2 2018

Bone Fracture-Pipeline by Laboratorios SALVAT SA, H2 2018

Bone Fracture-Pipeline by Novartis AG, H2 2018

Bone Fracture-Pipeline by Viking Therapeutics Inc, H2 2018

Bone Fracture-Dormant Projects, H2 2018

Bone Fracture-Dormant Projects, H2 2018 (Contd..1), H2 2018

Bone Fracture-Discontinued Products, H2 2018

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Biopharm GmbH

Bone Therapeutics SA

Entera Bio Ltd

ethris GmbH

Hemostemix Inc

Kolon TissueGene Inc

Kuros Biosciences AG

Laboratorios SALVAT SA

Novartis AG

Viking Therapeutics Inc

Bone Fracture Therapeutic Products under Development, Key Players in Bone Fracture Therapeutics, Bone Fracture Pipeline Overview, Bone Fracture Pipeline, Bone Fracture Pipeline Assessment

select a license
Single User License
USD 2000 INR 142720
Site License
USD 4000 INR 285440
Corporate User License
USD 6000 INR 428160

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com